C5 inhibitors have been approved for the treatment of diseases of complement overactivation, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and vasculitis (57). The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.